半定量99mTc MDM脑SPECT/CT与动态磁敏感对比增强MR灌注鉴别复发/残留胶质瘤与放射性坏死的比较研究
前瞻性纳入28例组织学证实的胶质瘤患者,术后标准放化疗后6个月行99mTc MDM SPECT/CT与DSCE-MRI,其中9例术后1-2周也行SPECT。复发组T/NT比值和nCBV均显著高于放射性坏死组,两者正相关(rho=0.823,P<0.0001)。两种技术灵敏度与特异度相当。
要点
- 复发组T/NT比值3.59±1.70显著高于放射性坏死组1.16±0.42。
- 复发组nCBV 5.16±2.30显著高于放射性坏死组1.63±0.94。
- T/NT与nCBV正相关(rho=0.823,P<0.0001)。
核心结论
- 联合MDM SPECT与DSCE MRI可能为鉴别胶质瘤肿瘤复发与放射性坏死提供准确方法。
研究设计与样本
- 前瞻性纳入28例组织学证实的胶质瘤患者(男性18例、女性10例;平均年龄41.4±15.03岁;IV级14例、III级7例、II级7例),计划术后标准放化疗。
- 所有患者术后/放化疗后6个月行99mTc MDM SPECT/CT和DSCE-MRI,28例中9例术后1-2周也行SPECT。
主要发现
- 复发组放射性示踪剂T/NT比值3.59±1.70显著高于放射性坏死组1.16±0.42。
- 复发组nCBV值5.16±2.30显著高于放射性坏死组1.63±0.94。
- T/NT比值与nCBV呈正相关(rho=0.823,P<0.0001)。
- ROC分析估计的T/NT比值截断值大于1.50(曲线下面积0.944±0.34),nCBV截断值大于2.12(曲线下面积0.931±0.39)。
- 结合SPECT/CT、DSCE-MRI和临床发现,分别诊断复发/残留胶质瘤18例和放射性坏死10例。
关键数值与推荐
- T/NT比值截断值大于1.50(AUC 0.944±0.34)。
- nCBV截断值大于2.12(AUC 0.931±0.39)。
- MDM SPECT/CT灵敏度92.0%、特异度78.6%;DSCE-MRI灵敏度92.0%、特异度71.4%,两种技术灵敏度与特异度相当。
临床怎么用
- 原文结论认为联合MDM SPECT与DSCE MRI可能为鉴别胶质瘤肿瘤复发与放射性坏死提供准确方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this study, Tc MDM (bis-methionine-DTPA) SPECT was used for the detection and differentiation of recurrent/residual glioma from radiation necrosis and the results were compared with dynamic susceptibility contrast-enhanced (DSCE)-MRI and clinical findings. MATERIALS AND METHODS: Twenty-eight patients (18 men and 10 women; mean ± SD age, 41.4 ± 15.03 years) with histologically proven glioma (grade IV, 14; grade III, 7; grade II, 7) who were planned for postsurgical standard radio/chemo therapy were recruited prospectively. All the patients underwent technetium Tc MDM SPECT/CT and DSCE-MRI imaging at 6 months after surgery/radio-chemotherapy, 9 of 28 patients also underwent SPECT imaging at 1 to 2 weeks after surgery. RESULTS: Tc MDM SPECT/CT analysis demonstrated significantly higher target to nontarget (T/NT) ratio of the radiotracer in tumor recurrence than in radiation necrosis (3.59 ± 1.70 vs 1.16 ± 0.42). Likewise, the normalized cerebral blood volume (nCBV) values in patients with tumor recurrence were also significantly higher than in radiation necrosis (5.16 ± 2.30 vs 1.63 ± 0.94). A positive correlation (rho = 0.823, P < 0.0001) between T/NT ratios and nCBV was observed. The cutoff T/NT ratios and nCBV values estimated by receiver operating characteristic analysis were greater than 1.50 (area under the curve, 0.944 ± 0.34) and greater than 2.12 (area under the curve, 0.931 ± 0.39), respectively. Combining the results of Tc MDM SPECT/CT, DSCE-MRI, and clinical findings, diagnosis of recurrent/residual glioma or radiation necrosis was made in 18 and 10 patients, respectively. Sensitivity and specificity of 2 techniques were comparable, that is, 92.0%: 78.6% for MDM SPECT/CT and of 92.0%: 71.4% for DSCE-MRI, respectively. CONCLUSION: Thus, combining MDM SPECT with DSCE MRI may provide an accurate method for differentiation of tumor recurrence from radiation-induced necrosis in glioma patients.
引用
- Rani N, Singh B, Kumar N, et al. Differentiation of Recurrent/Residual Glioma From Radiation Necrosis Using Semi Quantitative 99mTc MDM (Bis-Methionine-DTPA) Brain SPECT/CT and Dynamic Susceptibility Contrast-Enhanced MR Perfusion: A Comparative Study. Clin Nucl Med. 2018. PMID: 29356734. doi:10.1097/RLU.0000000000001943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。